RNA Editors and DNA Mutators: Cancer Heterogeneity Through Sequence Diversification
Abstract
(ISSN 2577-5790)
OBM Genetics is an international Open Access journal published quarterly online by LIDSEN Publishing Inc. It accepts papers addressing basic and medical aspects of genetics and epigenetics and also ethical, legal and social issues. Coverage includes clinical, developmental, diagnostic, evolutionary, genomic, mitochondrial, molecular, oncological, population and reproductive aspects. It publishes research articles, reviews, communications and technical notes, etc. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 15.0 days from acceptance to publication (median values for papers published in this journal in the second half of 2021, 1-2 days of FREE language polishing time is also included in this period).
Special Issue
Genetic Heterogeneity in Cancer
Submission Deadline: November 30, 2018 (Open) Submit Now
Guest Editor
Kakoli Das, PhD
Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, 8 College Road, Singapore 169857
Research Interests: cancer genomics, molecular genetics, genetic heterogeneity, precision medicine
About This Topic
Genetic heterogeneity in cancer is defined as the occurrence of genetic variation between tumors (inter tumor) and/or within individual tumors (intra tumor) partly due to genomic instability. The genomic instability may arise due to increased mutation rates, chromosomal instability, and microsatellite instability, exposure to mutagens such as smoking, UV rays and radiation. Each of these causes may have a significant impact on cancer genomes resulting in diversity within a tumor that may lead to different clinical outcomes and response to therapies. Recent cancer genomic studies, based on approaches such as multi-region profiling or ultra-deep sequencing have revealed varying degrees of genetic heterogeneity in different tumor types.Understanding tumor heterogeneity has been highlighted as a critical area for translational cancer research.
In this special issue of OBM Genetics, we have chosen topics that highlight the causes and implications of genetic heterogeneity in cancer of different types, methods to identify genetic heterogeneity in cancer, tackling genetic heterogeneity and suggest treatment strategies. Overall, this issue provides a complete understanding of the genetic heterogeneity driven by genomic instability, ways to limit genetic heterogeneity and tackle drug resistance in cancer.
Publication
RNA Editors and DNA Mutators: Cancer Heterogeneity Through Sequence DiversificationAbstract Cancer development and progression is strongly associated with somatic mutations. From oncogenic hits that initiate the primary tumor formation till metastasis, the tumor mutational burden (TBM) plays a prominent role in disease progression for the vast majority of cancer types. Heterogeneous mutational loads or genetic heterogeneity not onl [...] |
Clonal Heterogeneity in Non-Small Cell Lung Cancer and the Possible Role in Predicting Response to Treatment with Immune Checkpoint InhibitorsAbstract Immune oncology treatment with immune checkpoint inhibitors (ICIs) is revolutionizing therapeutic approach for advanced non-small cell lung cancer (NSCLC) patients, in terms of longer survival and improved quality of life. To date, the widely used and approved biomarker is programmed death ligand 1 (PD-L1) expression on tumour cells, but it [...] |
TOP